Loading clinical trials...

Methamphetamine-Quetiapine Interactions in Humans | Clinical Trials | Clareo Health

TERMINATEDEARLY_PHASE1

Methamphetamine-Quetiapine Interactions in Humans

Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study

NCT00567866•University of Arkansas

Summary

This study will test the ability of a medicine (Quetiapine) that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. This study will test the ability of a medicine that is used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it difficult for users to stop using it. The investigator thinks quetiapine will lessen the effects of methamphetamine.

Detailed Description

The specific goal of this project is to examine whether quetiapine will alter the behavioral effects of methamphetamine without producing major cardiovascular changes or toxic effects under controlled laboratory conditions. This goal will be accomplished using a methamphetamine challenge procedure in which quetiapine will be given orally prior to intravenous (iv) methamphetamine administration. This will allow rapid and systematic evaluation of the therapeutic potential of this medication. Results of this drug-interaction study will help determine further investigations of the clinical efficacy of this and other dopamine-active agents. We hypothesize that quetiapine will reduce the self-reported, performance and cardiovascular effects of methamphetamine.

Eligibility

Age

18 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Must be between the ages of 18-50.
•2. Must have experience with IV methamphetamine use, with self-reported recent history of weekly use being greater than the total administered in the study. Recent use will be confirmed by a urine toxicology screen positive for amphetamines. We will recruit moderate to frequent users of methamphetamine. Moderate use is defined as use from once or twice every six weeks to weekly. Frequent users are defined as individuals who use greater than weekly.
•3. Must have recent use confirmed by a urine toxicology screen positive for amphetamines.
•4. Must not be seeking treatment for methamphetamine abuse/dependence.

Exclusion Criteria

•1. Ill health (major cardiovascular, renal, endocrine, hepatic disorder).
•2. Current diagnosis of other drug or alcohol physical dependence (other than nicotine or caffeine).
•3. History of major organic psychiatric disorder (psychosis, schizophrenia, bipolar, mania) or significant psychiatric symptoms at the time of evaluation for study participation, including suicidal ideation.
•4. Pregnancy, plans to become pregnant or fertile women without adequate means of contraception.
•5. Present or recent use of over-the-counter or prescription psychoactive drug or drugs that would have major interaction with drugs to be tested.
•6. Medical contraindication to or prior serious adverse effects from methamphetamine or stimulants (i.e., seizures, cardiac arrest) or medical contraindication to test agents (see risks section). Significant physical or psychiatric illness which might impair the ability to safely complete the study or that might be complicated by the study drugs, including prior seizures (after age 8) or other active neurological disease or clinically significant abnormalities on physical examination or screening laboratory values.
•7. Current enrollment in a methamphetamine, alcohol, or other drug treatment program or current legal problems relating to methamphetamine, alcohol, or other drug use, including awaiting trial or supervision by a parole or probation officer
•8. Body Mass Index \>30 or \<18
•9. Currently trying to quit methamphetamine use or seeking treatment for methamphetamine use
•10. History of serious adverse event or hypersensitivity to methamphetamine or other study drugs
+3 more criteria

Locations (1)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Key Dates

Start Date

January 1, 2008

Primary Completion Date

September 1, 2009

Completion Date

September 1, 2009

Last Updated

July 13, 2010

Enrollment

ACTUAL participants

Conditions

Methamphetamine Dependence

Interventions

Quetiapine

DRUG

rTMS for Stimulant Use Disorders

NCT04907357

Cocaine Use DisorderMethamphetamine Abuse+7 more

View study

COMPLETED

Risk and Protective Factors for Rural Methamphetamine Dependence

NCT00882037

Methamphetamine Dependence

View study

COMPLETEDPHASE1

Buspirone as a Candidate Medication for Methamphetamine Abuse

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 13, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions